首页> 美国卫生研究院文献>Neuro-Oncology >P14.64 Primary Central Nervous System Lymphoma (PCNSL) with HD- MTX based chemotherapy: tolerability and results
【2h】

P14.64 Primary Central Nervous System Lymphoma (PCNSL) with HD- MTX based chemotherapy: tolerability and results

机译:P14.64主要中枢神经系统淋巴瘤(PCNSL)基于HD-MTX的化疗:可耐受性和结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Primary Central nervous system (CNS) lymphomas (PCNSL) are extranodal, malignant non- Hodgkin lymphomas of the diff use large B-cell type, confined to CNS. It accounts for up to 1% of all lymphomas and about 3% of all CNS tumours. The incidence continues to rise in immuno- competent elderly patients.Although the prognosis of PCNSL remains poor, it has improved in the past two decades as a result of better treatment strategies. However, treatment recommendations still result mainly from retrospective series or single-arm phase 2 studies and a few three completed randomised trials. We described a series of patients with newly diagnosis of PCNSL treated with modified-schedula published by Omuro
机译:初级中枢神经系统(CNS)淋巴瘤(PCNSL)是外亚的衍生物的恶性非霍奇金淋巴瘤使用大型B细胞类型,限制在CNS上。它占所有淋巴瘤的1%,占所有CNS肿瘤的约3%。免疫老年患者的发病率持续上升。虽然PCNSL的预后仍然贫困,但由于更好的治疗策略,它在过去二十年中有所改善。然而,治疗建议仍然主要来自回顾性系列或单臂阶段2研究和几次完成随机试验。我们描述了一系列患者新诊断的PCNSL治疗,由OMURO发布的修改调度

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号